Although left-to-right shunting may occur through a patent foramen ovale in infants with mitral or aortic valve atresia, we are unaware of previous hemodynamic or surgical evidence of a similar ...

The U.S. Food and Drug Administration has approved Edwards Lifesciences' SAPIEN 3 platform, a transcatheter aortic valve ...

New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a ...

The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

Aortic stenosis is a narrowing of the aortic valve opening, which restricts blood flow from the heart to the rest of the body ...

It often starts with sudden, sharp chest pain that feels unlike anything you have experienced before. It might spread to your ...

A transcatheter aortic valve replacement platform was approved for severe asymptomatic aortic stenosis. Edwards Lifesciences’ TAVR platform is the first to be approved in this population.

Asymptomatic patients with severe aortic stenosis can now undergo transcatheter aortic valve replacement, thanks to the US Food and Drug Administration’s approval of the new indication for the balloon ...

The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for the treatment of patients with asymptomatic severe ...

Electronic provider notification led to more aortic valve replacement procedures after a diagnosis of severe aortic stenosis vs. usual care. There was a trend toward the intervention reducing ...

The two companies have entered into a strategic partnership to exclusively commercialize Braile’s Transcatheter Aortic Valve Implantation (TAVI) technology across Europe, India, and other ...